Compare BWAY & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | ALLO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.8M | 539.4M |
| IPO Year | N/A | 2018 |
| Metric | BWAY | ALLO |
|---|---|---|
| Price | $16.49 | $2.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $13.25 | $8.35 |
| AVG Volume (30 Days) | 144.8K | ★ 14.4M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $309.69 | N/A |
| Revenue Next Year | $26.21 | $142,416.42 |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.59 | $0.86 |
| 52 Week High | $26.63 | $4.46 |
| Indicator | BWAY | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 47.02 |
| Support Level | $14.56 | $1.92 |
| Resistance Level | $16.63 | $2.71 |
| Average True Range (ATR) | 0.71 | 0.35 |
| MACD | 0.41 | -0.04 |
| Stochastic Oscillator | 95.83 | 17.43 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.